A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Shinsuke IidaTohru IzumiTakuya KomenoYasuhito TeruiTakaaki ChouTakashi IkedaDeborah BergShinichi FukunagaKenkichi SugiuraMakoto SasakiPublished in: International journal of clinical oncology (2021)
NCT02917941; date of registration September 28, 2016.